Last reviewed · How we verify
VB-111
At a glance
| Generic name | VB-111 |
|---|---|
| Sponsor | Vascular Biogenics Ltd. operating as VBL Therapeutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) (PHASE2)
- VB-111 in Surgically Accessible Recurrent/Progressive GBM (PHASE2)
- A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) (PHASE3)
- A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer (PHASE1, PHASE2)
- Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme (PHASE1, PHASE2)
- A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) (PHASE3)
- Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer (PHASE2)
- A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VB-111 CI brief — competitive landscape report
- VB-111 updates RSS · CI watch RSS
- Vascular Biogenics Ltd. operating as VBL Therapeutics portfolio CI